TGFB1 and cancer: As TGF-β enhances the metastatic phenotype of cancer cells, and increases production of osteolytic factors,27 MDA-MB-231 were treated with TGF-β1 (5 ng·mL−1, w/v) or PBS (veh) as a control, prior to LIV.